Related by context. All words. (Click for frequent words.) 74 Subgroup analyzes 73 nonrandomized 69 multicenter trials 69 placebo controlled trials 69 Subgroup analysis 68 prospectively defined 68 ALLHAT 68 multivariate analyzes 68 randomized trials 68 RCTs 68 Meta analyzes 68 substudy 67 subanalysis 67 randomized controlled trials RCTs 67 lipid lowering therapy 67 SCD HeFT 67 Kaplan Meier analysis 67 liver transplant recipients 66 KRAS status 66 VADT 66 secondary efficacy endpoints 66 randomized clinical trials 66 perioperative complications 66 ConclusionThis 66 efficacy endpoint 66 NATRECOR ® 66 paclitaxel eluting stents 66 placebo controlled studies 66 AVERROES 66 HCV SPRINT 66 ACCORD Lipid 66 SLNB 65 PREVENT IV 65 meta analyzes 65 prospective randomized controlled 65 riociguat 65 β blockers 65 SYNTAX trial 65 Observational studies 65 FDG PET 65 chemoradiotherapy 65 noninferiority 65 HORIZONS AMI trial 65 ROCKET AF 65 selenium supplementation 65 adjuvant therapies 65 PCI ExTRACT TIMI 65 QTc prolongation 65 observational studies 65 logistic regression analyzes 65 logistic regression models 65 RE LY 65 locoregional recurrence 65 adjuvant therapy 65 univariate analyzes 65 ATACAND 65 covariate 65 MERLIN TIMI 64 genotypic resistance 64 epidemiologic studies 64 multivariable analysis 64 STRIDE PD 64 phase IIIb 64 CANCIDAS 64 carotid artery stenting 64 metaanalysis 64 cerebral microbleeds 64 generalizability 64 #F FDG PET 64 dosage regimens 64 placebo controlled clinical 64 chest radiographs 64 lipid lowering drugs 64 randomized clinical 64 randomized controlled trials 64 beta blocker therapy 64 MADIT II 64 RE LY ® 64 Doxil ® 64 sonographic findings 64 antiplatelet therapy 64 CYPHER Stent 64 pharmacokinetic PK 64 postoperative chemotherapy 64 MEND CABG 64 renal tumors 63 PLCO 63 Randomized trials 63 univariate 63 Epidemiologic studies 63 LV dysfunction 63 Kaplan Meier curve 63 RE LY trial 63 definite stent thrombosis 63 prostate cancer CaP 63 metastatic RCC 63 SABCS 63 ToGA 63 multicenter randomized controlled 63 sentinel node biopsy 63 multicenter placebo controlled 63 residual confounding 63 periprocedural MI 63 Univariate analysis 63 Secondary efficacy endpoints 63 APTIVUS r 63 fluvastatin 63 GFT# 63 androgen suppression 63 univariate analysis 63 APTIVUS 63 eprotirome 63 rFVIIa 63 TRITON TIMI 63 lymphadenectomy 63 perioperative morbidity 63 CALGB 63 preoperative chemotherapy 63 pharmacokinetic studies 63 antiplatelet drugs 63 ONTARGET 63 antiangiogenic agents 63 CARE HF 63 BENICAR HCT 63 carotid stenting 63 placebo controlled clinical trials 63 bone scintigraphy 63 morphometric vertebral fractures 63 plasma pharmacokinetics 62 KRAS mutation 62 beta carotene supplementation 62 mCRC patients 62 MADIT CRT trial 62 sirolimus eluting stents 62 prophylactic cranial irradiation 62 prognostic variables 62 neoadjuvant therapy 62 multivariate logistic regression 62 PROactive study 62 SPARCL 62 periprocedural 62 immunohistochemical 62 methodological limitations 62 Zevalin consolidation 62 DLTs 62 vitro experiments 62 PRIMO CABG2 62 recurrent GBM 62 HIV HCV coinfected 62 dosing cohort 62 olaparib 62 mycophenolate mofetil 62 comorbid conditions 62 coinfected patients 62 immunohistochemical staining 62 F FDG PET 62 Kaplan Meier curves 62 relapsed MM 62 intravesical therapy 62 coronary stenosis 62 comorbidities 62 meta analysis 62 randomized Phase III 62 carotid IMT 62 GnRH agonists 62 duplex ultrasonography 62 histopathological 62 nomograms 62 BARI 2D 62 Logistic regression analysis 62 lipid abnormalities 62 confirmatory clinical 62 fosbretabulin 62 conditional logistic regression 62 HCV RESPOND 2 62 adenoma recurrence 62 thromboprophylaxis 62 Candesartan 62 PROSTVAC TM 62 prognostic factors 62 thromboembolic events 62 multicentre randomized 62 BEXXAR Therapeutic Regimen 62 ischemic cardiomyopathy 62 neoadjuvant 62 metabolic parameters 62 antiangiogenic therapy 62 Carotid Revascularization Endarterectomy vs. 62 Vectibix monotherapy 62 non selective NSAIDs 62 histologies 62 axitinib 62 Stenting Trial CREST 62 T2DM 62 nab paclitaxel 62 neoadjuvant chemotherapy 62 strontium ranelate 62 cediranib 62 symptomatic VTE 62 pancreatic adenocarcinoma 62 antioxidant supplementation 62 pharmacokinetic parameters 62 subclinical hypothyroidism 62 Dose escalation 62 prespecified 62 DAPT 62 logistic regression analysis 62 ExTRACT TIMI 61 confounding variables 61 HAART regimens 61 elacytarabine 61 virologic response 61 intravenous bisphosphonates 61 ADAGIO study 61 immunohistochemical analysis 61 patients undergoing CABG 61 methotrexate therapy 61 AIM HIGH 61 hip resurfacing arthroplasty 61 UKPDS 61 adjuvant radiotherapy 61 Prostate Lung Colorectal 61 BRIM3 61 Randomized clinical trials 61 BCIRG 61 placebo controlled randomized 61 pharmacodynamic effects 61 heavily pretreated 61 preclinically 61 nonrandomized studies 61 CTEPH 61 enzastaurin 61 methodologic 61 FOLPI 61 chemoprevention trials 61 ABSORB trial 61 GAMMAGARD 61 randomized Phase 2b 61 prospective observational studies 61 adjuvant radiation 61 Thrombolysis 61 conventional angiography 61 ximelagatran 61 NHANES III 61 paricalcitol 61 chemotherapeutic regimens 61 randomized Phase IIb 61 heavily pretreated patients 61 APPRAISE 61 K ras mutations 61 tumor histology 61 adjuvant chemotherapy 61 trials RCTs 61 PLCO trial 61 trastuzumab Herceptin ® 61 nonclinical studies 61 CALGB # [001] 61 adecatumumab 61 virologic responses 61 oral Xeloda 61 eculizumab therapy 61 OPCAB 61 Randomized controlled 61 efficacy endpoints 61 PIX# [002] 61 aldosterone antagonist 61 ACUITY trial 61 multiple logistic regression 61 Multivariate logistic regression 61 postoperative complication 61 IMPROVE HF 61 randomized controlled clinical trials 61 perioperative mortality 61 ICD therapy 61 multicenter randomized 61 correlational 61 exploratory endpoints 61 antitumour activity 61 elotuzumab 61 teriflunomide 61 serum creatinine levels 61 cardioprotective effects 61 hsCRP levels 61 everolimus eluting stents 61 PFO migraine 61 HyQ 61 multicenter randomized placebo controlled 61 CAMMS# 61 lymph node dissection 61 MTWA testing 61 EchoCRT 61 ABCSG 61 SORT OUT III 61 unmeasured confounders 61 Phase 2b study 61 viral kinetic 61 retrospective cohort 61 lipid lowering agents 61 prospective randomized 61 HeFT 61 biochemical recurrence 61 prospective multicenter 61 scintigraphic 61 ICD implantation 60 FDG-PET/CT 60 prospective multicentre 60 EBUS FNA 60 SLN biopsy 60 Multivariate analysis 60 nephron sparing surgery 60 hepatotoxicity 60 EGFR mutations 60 oncologic outcomes 60 eplerenone 60 postoperative mortality 60 RSD# oral 60 extramedullary 60 randomized controlled clinical 60 neoadjuvant treatment 60 dose escalation Phase 60 longitudinal studies 60 urine cytology 60 CIMZIA ™ 60 revascularization procedures 60 galiximab 60 prucalopride 60 randomized multicentre 60 sentinel lymph node biopsy 60 mammographic density 60 composite endpoint 60 CHAMPION PLATFORM 60 pharmacokinetic interactions 60 multicenter randomized clinical 60 NO# [002] 60 left ventricular dysfunction 60 imatinib therapy 60 etiologic 60 NSABP B 60 unblinded 60 STEP BD 60 APEX AMI trial 60 histopathologic 60 Digital Mammographic Imaging 60 sorafenib Nexavar 60 stratifying patients 60 antihypertensive therapy 60 recurrent glioblastoma multiforme 60 valvulopathy 60 virologic failure 60 multivariate Cox 60 CYP#D# genotype 60 antimicrobial prophylaxis 60 antihypertensive drugs 60 conventional coronary angiography 60 prognostic significance 60 TAXUS VI 60 myeloproliferative diseases 60 bosentan 60 confounders 60 prostate carcinoma 60 nesiritide 60 REACH Registry 60 percutaneous cryoablation 60 dose statin therapy 60 prospective observational cohort 60 colorectal liver metastases 60 Multiple logistic regression 60 postoperative radiotherapy 60 cinacalcet 60 lymph node involvement 60 pharmacodynamic 60 logistic regression model 60 bezafibrate 60 Intervention Effectiveness CATIE 60 PRIMO CABG 60 PRECiSE 60 SIMPADICO 60 carotid endarterectomy CEA 60 androgen deprivation 60 ivabradine 60 SPIRIT FIRST 60 HGPIN 60 BRIM2 60 iniparib 60 Ceplene/IL-2 60 thromboembolic complications 60 EDEMA4 60 GOUT 60 CA4P 60 clinicopathological 60 intensive statin therapy 60 metastatic HRPC 60 Cardiopulmonary bypass 60 XIENCE V PROMUS Stent 60 landmark ATHENA 60 TEAEs 60 attain statistical significance 60 multivariate analysis 60 TAXUS IV 60 dose escalation 60 postmenopausal hormones 60 dosing regimens 60 prospective randomized multicenter 60 phase IIb study 60 Logistic regression 60 paroxysmal AF 60 pharmacodynamic PD 60 NNRTI resistance 60 incomplete revascularization 60 probiotic supplementation 60 antibiotic prophylaxis 60 gefitinib Iressa 60 chemoradiation 60 EGFR mutation status 60 RTOG 60 multivariable analyzes 60 achieved statistical significance 60 tigecycline 60 thrombolytic therapy 60 CHAMPION PCI 60 genetic polymorphisms 60 mRCC 60 Pharmacokinetic parameters 60 anti leukemic 60 ERSPC 60 tecarfarin 60 skeletal metastases 60 PCa 60 secondary efficacy endpoint 60 angiographic outcomes 60 radical nephrectomy 60 regression analyzes 60 retrospective cohort study 60 INCB# [003] 60 MERIT ES 60 reinfarction 60 CVD mortality 60 troponins 60 Multivariate analyzes 60 contralateral breast cancer 60 randomized multicenter 60 platelet reactivity 60 SYMMETRY trial 60 meta analytic 60 brivaracetam 60 empiric 60 vicriviroc 60 multivessel disease 60 ganetespib 60 HER2 positive metastatic breast 60 cilostazol 60 caspofungin 60 PNH patients 60 meta regression 60 intensive lipid lowering 60 Bezielle 60 eptifibatide 59 concomitant medications 59 randomized controlled trial 59 thrombus aspiration 59 vertebral fracture 59 H. pylori eradication 59 medically inoperable 59 non squamous NSCLC 59 therapeutic regimens 59 Poisson regression 59 carotid artery stenting CAS 59 liver biopsies 59 SYNTAX 59 pegylated liposomal doxorubicin 59 stepwise logistic regression 59 EURIDIS 59 transrectal ultrasound guided 59 TAXUS Stent 59 HIF PHI 59 cystectomy 59 reach statistical significance 59 Angiographic 59 multicentric 59 post hoc 59 prospectively randomized 59 radiochemotherapy 59 Phase 2a trial 59 pharmacokinetics PK 59 dose proportionality 59 florbetaben 59 concurrent chemoradiation 59 prospective longitudinal 59 carotid stenosis 59 CYPHER ® Sirolimus eluting 59 Phase IIB 59 rALLy trial 59 immunosuppressive agents 59 MADIT CRT 59 randomized blinded 59 IV bisphosphonates 59 posaconazole 59 nephrectomy 59 pharmacodynamic endpoints 59 cytoreductive nephrectomy 59 idraparinux 59 CYPHER R Sirolimus eluting 59 vismodegib 59 prospective observational 59 reboxetine 59 serum calcium 59 virological response 59 MDRD 59 ImmuKnow assay 59 Pharmacokinetic 59 obscure gastrointestinal bleeding 59 Lipid Lowering Treatment 59 covariates 59 prognostic indicators 59 ruboxistaurin 59 postintervention 59 micafungin 59 oral anticoagulation 59 ascending dose 59 Pharmacokinetic PK 59 Clinical Antipsychotic Trials 59 randomized multicenter trial 59 clinico pathological 59 nonresponders 59 perfusion abnormalities 59 mg/m2 cohort 59 prostate cancer PCa 59 Phase Ib clinical 59 BOLDER II 59 prespecified secondary 59 randomized controlled 59 satraplatin Phase 59 HSCT 59 EDEMA3 trial 59 adrenalectomy 59 pharmacodynamics PD 59 relapsed AML 59 cystatin C 59 lintuzumab 59 coadministration 59 doxorubicin docetaxel 59 NSTE ACS 59 SGAs 59 underwent resection 59 nodal metastases 59 INC# 59 transurethral resection 59 pharmacological approaches 59 DES implantation 59 Triolex 59 virologic 59 advanced adenomas 59 velafermin 59 colorectal neoplasia 59 SNP rs# [002] 59 cytoreductive surgery 59 antithrombotic therapy 59 MIRCERA 59 alteplase 59 EUS FNA 59 pharmacokinetic characteristics 59 breast carcinoma 59 lymph node metastases 59 nondiabetic patients 59 PRE SURGE 59 SPIRIT IV 59 posttreatment 59 MEND CABG II 59 sotalol 59 thromboembolic disease 59 ELACYT 59 pharmacologic intervention 59 statin therapy 59 carotid plaques 59 gadobutrol 59 delafloxacin 59 nonischemic 59 timepoints 59 neuroimaging studies 59 coronary angiography 59 statistically nonsignificant 59 allogeneic transplant 59 Secondary endpoints 59 viral kinetics 59 solifenacin 59 Non inferiority 59 MGUS 59 Bonferroni correction 59 placebo controlled Phase 59 revascularizations 59 clinical endpoints 59 ANCHOR trial 59 EEG abnormalities 59 tanespimycin 59 liposomal amphotericin B 59 liver metastasis 59 Long Lesion 59 phase IIb 59 surrogate markers 59 familial clustering 59 antiepileptics 59 double blinded randomized 59 lipid parameters 59 Prostate Cancer Prevention 59 calcineurin inhibitors 59 myocardial infarctions 59 pelvic lymphadenectomy 59 Mechanistic studies 59 ELCAP 59 NATRECOR R 59 multicentre 59 serum phosphorous 59 methodological flaws 59 multivariate regression analysis 59 drug eluting stent implantation 59 liver metastases 59 postoperative morbidity 59 elective PCI 59 ALISTA 59 renal transplantation 59 Afatinib 59 surrogate endpoint 59 testosterone supplementation 59 thromboembolism 59 iPrEx study 59 intact parathyroid hormone 59 NICE SUGAR 59 sleeve lobectomy 59 VTE prophylaxis 59 multicenter study 59 Vitaxin 59 HYVET 59 pharmacodynamic properties 59 phase IIa 59 ZACTIMA 59 TACE 59 active comparator 59 pharmacodynamic parameters 59 Nesiritide 59 advanced neoplasia 59 multicenter Phase II 59 Rasilez Tekturna 59 tirofiban 59 Radical prostatectomy 59 antitumor effect 59 HER2 expression 59 DHA supplementation 59 rt PA 59 rosuvastatin 58 histological subtype 58 carotid plaque 58 pheochromocytoma 58 Conclusions 58 Cardiotoxicity 58 ASCEND HF 58 elevated CRP 58 Prostate AdenoCarcinoma Treatment 58 pCR 58 NEVO ™ 58 EVEREST II 58 clinicopathologic 58 blind randomized controlled 58 AVADO 58 warfarin therapy 58 Longitudinal studies 58 ß blockers 58 abciximab 58 MDRD equation 58 Percutaneous Coronary Intervention 58 IFN beta 58 Univariate 58 AVOREN 58 APOPTONE 58 MAGE A3 ASCI 58 COPERNICUS 58 CYP#C# genotype 58 adalimumab 58 fondaparinux 58 Primary endpoints 58 LUX Lung 58 vitamin D supplementation 58 stent implantation 58 myocardial ischemia 58 immunosuppressive regimens 58 FASLODEX 58 deferiprone 58 transthoracic 58 dose escalation phase 58 KIF6 carriers 58 FDG PET imaging 58 coronary revascularization 58 Events MACE 58 HuMax EGFr 58 assessing T DM1 58 pertuzumab 58 HMG CoA reductase inhibitors 58 EDEMA3 58 Xanafide 58 pneumonectomy 58 Phase III randomized controlled 58 PROSTVAC VF 58 transabdominal 58 ECASS 58 CLBP 58 partial nephrectomy 58 double blinded placebo 58 gadolinium enhanced 58 cranial irradiation 58 glycoprotein IIb IIIa inhibitors 58 pretransplant 58 neratinib 58 Coronary Artery Bypass Graft 58 adjuvant trastuzumab 58 varicoceles 58 clinically meaningful differences 58 CCX# 58 multicenter 58 Baseline characteristics 58 multivariable logistic regression 58 overlapping toxicities 58 cobiprostone 58 Cochrane Systematic Review 58 hemorrhagic complications 58 neuropsychiatric symptoms 58 CTAP# Capsules 58 preoperative diagnosis 58 radical cystectomy 58 chlorthalidone 58 relapsed SCLC 58 poor metabolizers 58 RRMS patients 58 Elocalcitol 58 histologic examination 58 Phase IIIb study 58 Neoadjuvant 58 prospective randomized placebo 58 allogeneic HSCT 58 PROMACTA 58 hyperoxaluria 58 thoracoscopic lobectomy 58 macrovascular disease 58 Thal Dex 58 tamsulosin 58 NEVO RES 58 malignant polyps 58 authors hypothesized 58 curative resection 58 afatinib 58 antiretroviral naïve 58 postoperative complications 58 Acute Myocardial Infarction 58 liver resection 58 endometrial carcinoma 58 prospectively stratified 58 pain palliation 58 serum vitamin D 58 montelukast 58 taxane therapy 58 PITX2 methylation 58 Phase #b/#a trial 58 Adjuvant chemotherapy 58 echocardiographic 58 nonoperative 58 PREZISTA r 58 glatiramer acetate 58 factorial design 58 temsirolimus 58 oral rivaroxaban 58 aldosterone antagonists 58 Hepatocellular Carcinoma HCC 58 atrasentan 58 pentoxifylline 58 preclinical efficacy 58 antiarrhythmic drug 58 cardiovascular morbidity 58 Carfilzomib 58 GnRH agonist 58 confounder 58 epidemiological studies 58 Azedra 58 renal dysfunction 58 FDA defined valvulopathy 58 AGILECT R 58 inflammatory biomarkers 58 breast cancer subtypes 58 ritonavir boosted 58 registrational trial 58 statistically significant p = 58 mucinous 58 endoscopic ultrasonography 58 CYPHER ® Stent 58 STICH trial 58 renal artery stenosis 58 histologic subtypes 58 Acute Ischemic Stroke 58 ZD# [001] 58 IL#B 58 stenoses 58 secondary endpoints 58 undetectable HBV DNA 58 stage IIIB 58 gemcitabine Gemzar 58 subclinical hyperthyroidism 58 observational cohort 58 prostate TURP 58 tarenflurbil 58 DMARD 58 recurrent malignant glioma 58 mesotheliomas 58 ibandronate 58 familial aggregation 58 multimodality therapy 58 trastuzumab emtansine T DM1 58 superficial bladder cancer 58 transesophageal 58 Sensitivity analyzes 58 thyroidectomy 58 DCE MRI 58 nonfatal MI 58 TOLAMBA 58 antithrombotic therapies 58 HNSCC 58 BR.# 58 DHEA supplementation 58 Pemetrexed 58 Phase Ib study 58 pharmacokinetic PK profile 58 antiplatelet therapies 58 Neuradiab 58 hamartomas 58 Phase Ib 58 Aplidin 58 BRCA2 mutation carriers 58 macrovascular events 58 FOLFIRI 58 unblinding 58 BRCA mutation carriers 58 ALB # 58 biologic plausibility 58 aortic insufficiency 58 vaginal hysterectomy 58 differentiated thyroid 58 PXD# 58 recurrent miscarriage 58 spirometric 58 monoinfected patients 58 metastatic lung cancer 58 Phase III VISTA 58 darunavir ritonavir 58 dyslipidaemia 58 transient elastography 58 Aggressive Reduction 58 reperfusion therapy 58 nodal metastasis 58 KRAS mutations occur 58 ascertainment bias 58 PARTNER Trial 58 follicular adenoma 58 basal bolus regimen 58 xenograft models 58 MGd 58 Protelos 58 thyroid nodules 58 MMSE score 58 CIMZIA TM certolizumab pegol 58 crizotinib PF # 58 hemodynamically significant 58 variance ANOVA 58 hepatectomy 58 bivariate 58 alvespimycin 58 WHEL 58 dexrazoxane 58 GRAVITAS trial 58 dose cohorts 58 phase Ib 58 phase IIb clinical 58 Prospective Randomized 58 azacitidine 58 figitumumab 58 dipyridamole plus 58 pulmonary toxicity 58 platelet inhibitor 58 phase 2a 58 IOP lowering 58 comorbidity 58 aromatase inhibitors AIs 58 biochemical abnormalities 58 standard chemotherapy regimens 58 mg/m2 dose 58 multivariable Cox 58 sunitinib 58 pulmonary nodules 58 BRAF mutation 58 ASTEROID 58 Zemplar Capsules 58 mTOR inhibition 58 budesonide foam 58 5-fluorouracil/leucovorin 58 reoperations 58 adenotonsillectomy 58 Vertos II 58 histologically confirmed 58 CR nPR 58 methotrexate monotherapy 58 tumor subtypes 58 pressor response 58 abatacept 58 ritonavir boosted lopinavir 58 landmark ATHENA study 58 docetaxel chemotherapy 58 specific antigen PSA 58 Cytoxan 57 antiarrhythmic drugs 57 immunosuppressive regimen 57 desvenlafaxine succinate 57 rtPA 57 LHRH agonists 57 antihypertensive medications 57 noncardiac 57 PSN# [002] 57 irbesartan 57 teriparatide 57 lumbar spine BMD 57 lenalidomide dexamethasone 57 radiographic findings 57 Phase IIIb 57 Lp PLA 2 57 specified secondary endpoints 57 microbleeds 57 psychiatric comorbidity 57 phosphate binders 57 susceptibility loci 57 gene polymorphisms 57 insulin degludec 57 MitraClip device 57 tocilizumab 57 clevidipine 57 angiotensin converting enzyme inhibitors 57 colorectal neoplasms 57 Renal Cell Carcinoma RCC 57 Ophena TM 57 receptor tyrosine kinase inhibitor 57 HIF PH inhibitors 57 postmenopausal hormone therapy 57 epithelial tumors 57 vitro studies 57 ARCOXIA 57 UA NSTEMI 57 relapsed ALL 57 nonoperative treatment 57 lipid lowering 57 hsCRP 57 histologic 57 plasma kallikrein inhibitor 57 pT2 57 postsurgical 57 NLX P# 57 VATS lobectomy 57 recanalization 57 Visipaque 57 adjuvant systemic 57 nulliparous women 57 salpingo oophorectomy 57 visceral metastases 57 randomized placebo controlled 57 IPAH 57 SPIRIT III 57 certolizumab 57 squamous histology 57 TMC# C# 57 plain radiographs 57 CR# vcMMAE 57 decitabine 57 ARBITER 6 57 iodixanol 57 coronary interventions 57 Echocardiographic 57 serum concentrations 57 lipid lowering therapies 57 BMS# 57 Phase #/#a 57 maximally tolerated dose 57 SWOG 57 LVNC 57 PROSTVAC ® 57 ularitide 57 Tumor Response 57 Cholesterol Levels SPARCL 57 Allovectin 7 ® 57 colorectal adenoma 57 ruxolitinib 57 CsA 57 pharmacogenetic testing 57 polycythemia vera PV 57 atherosclerotic renal artery stenosis 57 ILLUMINATE 57 dose titration 57 chest radiography